retatrutide causing diarrhea More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Phase Retatrutide Weight Loss Results:Trial Data

Robert Kushner, Professor of Medicine, Northwestern University Your healthcare provider will create a tailored plan for you

The glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metabolism , 2008

The science is more complex than the headline suggests, highlighting the importance of looking beyond headlines and interpreting the full evidence base

What has become increasingly clear is that GLP-1 receptors are expressed throughout the bodyin the brain, heart, endothelium, pancreas, and immune cellsmaking this pathway a powerful modulator of systemic aging processes

Retatrutide is an investigational Phase 3 compound